BridgeBio Oncology Therapeutics Statistics Share Statistics BridgeBio Oncology Therapeutics has n/a
shares outstanding. The number of shares has increased by 244.74%
in one year.
Shares Outstanding n/a Shares Change (YoY) 244.74% Shares Change (QoQ) 236.88% Owned by Institutions (%) n/a Shares Floating 447.85K Failed to Deliver (FTD) Shares 1,673 FTD / Avg. Volume 0.76%
Short Selling Information The latest short interest is 78.08K, so 0% of the outstanding
shares have been sold short.
Short Interest 78.08K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is 22.98 and the forward
PE ratio is -5.53.
BridgeBio Oncology Therapeutics's PEG ratio is
0.
PE Ratio 22.98 Forward PE -5.53 PS Ratio 0 Forward PS n/a PB Ratio 0.93 P/FCF Ratio -228.69 PEG Ratio 0
Financial Ratio History Enterprise Valuation BridgeBio Oncology Therapeutics has an Enterprise Value (EV) of 172.98M.
EV / Sales 0 EV / EBITDA 22.76 EV / EBIT -226.47 EV / FCF -226.47
Financial Position The company has a current ratio of 10.4,
with a Debt / Equity ratio of 0.
Current Ratio 10.4 Quick Ratio 10.4 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is 4.03% and Return on Invested Capital is -0.3%.
Return on Equity 4.03% Return on Assets 3.91% Return on Invested Capital -0.3% Revenue Per Employee n/a Profits Per Employee n/a Employee Count undefined Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 18.5% in the
last 52 weeks. The beta is 0.08, so BridgeBio Oncology Therapeutics's
price volatility has been higher than the market average.
Beta 0.08 52-Week Price Change 18.5% 50-Day Moving Average 10.44 200-Day Moving Average 10.68 Relative Strength Index (RSI) 63.29 Average Volume (20 Days) 220,626
Income Statement
Revenue n/a Gross Profit n/a Operating Income -584K Net Income 7.6M EBITDA 7.6M EBIT 7.6M Earnings Per Share (EPS) 0.46
Full Income Statement Balance Sheet The company has 1.7M in cash and 0 in
debt, giving a net cash position of 1.7M.
Cash & Cash Equivalents 1.7M Total Debt n/a Net Cash n/a Retained Earnings -3.73M Total Assets 197.39M Working Capital -1.75M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -763.82K
and capital expenditures 0, giving a free cash flow of -763.82K.
Operating Cash Flow -763.82K Capital Expenditures n/a Free Cash Flow -763.82K FCF Per Share -0.05
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
